Cuprina MENA Co. Ltd, a 49%-owned associate of Cuprina Holdings (Cayman) Ltd, has completed the establishment of a laboratory in Saudi Arabia designed to manufacture MEDIFLY maggot debridement therapy for chronic wound treatment. This new facility will supply the therapy throughout the Middle East and North Africa region. Additionally, Cuprina MENA has acquired exclusive rights to market medicinal leeches in the Gulf Cooperation Council countries, a treatment increasingly used for medical conditions such as venous congestion and to enhance tissue healing post-surgery. These strategic advancements are expected to broaden Cuprina's market presence in the MENA and GCC regions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。